Principal Financial Group Inc. Purchases 82,953 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Principal Financial Group Inc. boosted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 67.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 205,864 shares of the company's stock after purchasing an additional 82,953 shares during the period. Principal Financial Group Inc. owned 0.35% of Twist Bioscience worth $9,301,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of TWST. Caprock Group LLC boosted its holdings in shares of Twist Bioscience by 2.9% in the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company's stock valued at $387,000 after buying an additional 220 shares during the last quarter. Signaturefd LLC lifted its stake in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. Arizona State Retirement System grew its position in shares of Twist Bioscience by 1.9% in the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company's stock valued at $798,000 after acquiring an additional 308 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock worth $457,000 after purchasing an additional 312 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Twist Bioscience by 2.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company's stock valued at $734,000 after purchasing an additional 363 shares during the period.

Insider Activity

In other news, CEO Emily M. Leproust sold 14,334 shares of the company's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the sale, the chief executive officer now owns 589,552 shares of the company's stock, valued at approximately $26,294,019.20. This represents a 2.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the completion of the transaction, the chief accounting officer now directly owns 45,620 shares in the company, valued at $2,034,652. This trade represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 105,415 shares of company stock worth $4,767,399. Corporate insiders own 3.92% of the company's stock.

Twist Bioscience Price Performance

Twist Bioscience stock traded down $0.76 during midday trading on Tuesday, hitting $46.47. The company's stock had a trading volume of 512,799 shares, compared to its average volume of 935,719. The company has a 50-day moving average price of $45.70 and a two-hundred day moving average price of $46.59. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The company has a market cap of $2.76 billion, a price-to-earnings ratio of -12.91 and a beta of 1.82.

Wall Street Analyst Weigh In

TWST has been the subject of a number of research analyst reports. Barclays reduced their price target on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Tuesday, November 19th. Evercore ISI boosted their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Scotiabank raised their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a report on Tuesday, November 19th. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a research report on Thursday, October 17th. Finally, Robert W. Baird increased their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.